A Phase 3 interventional study of rhIGF-1 (mecasermin, Tercica, Inc.) in Growth Disorders and Insulin-Like Growth Factor-1 Deficiency, sponsored by Ipsen. Completed at 1 site in United States. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Ipsen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Growth Disorders with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Growth Disorders · United States.
Among the 25 studies in Growth Disorders with a site in United States, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2004, is one of 4 in phase 3, and was the 3rd registered.
227 studies on the registry are indexed under Growth Disorders; 25 are open to participants now.
Browse Growth Disorders studies →4 of the 25 studies in Growth Disorders with a site in United States are open now. Recruiting first, the newest first:
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 4 more countries
Ages 0 yrs–32 mo
Northwell Health · Sites in United States
Ages 5–15 · Healthy volunteers
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 3 mo–100 yrs
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 1 mo–99 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Growth Disorders studies recruiting now, 3 (17%) set no upper age limit and 13 (72%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 3 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 5 · Phase 4 1
First in 1983; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 137 is below the median of 413 across 143 interventional studies indexed under Growth Disorders.
Median enrollment 50 across the 17 interventional studies, 933 across the 8 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 25 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 290 studies on the registry; 18 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 3 studies filed under Growth Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Growth Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of prepubertal children with short stature associated with low IGF-1 levels but who produce sufficient growth hormone (GH). Subjects will be randomized to either an observation arm or to active treatment.
Prepubertal growth failure associated with primary IGF-1 deficiency (IGFD). Primary IGFD is a term that has been used to describe patients with intrinsic cellular defects in GH action. In this protocol, primary IGFD is defined as short stature (height standard deviation score[SDS]\<-2 below the mean for age and gender), low serum IGF-1 (IGF-1 SDS \<-2 below the mean for age and gender), and levels of growth hormone (GH) that are normal (≥7ng/mL) after a GH stimulation test. Primary IGFD is believed to result from a lower than normal ability to produce IGF-1 when exposed to normal levels of GH, i.e., a type of GH insensitivity or GH resistance.
This trial is one year, randomized, open label, observation-controlled, parallel-dose comparison efficacy and safety study conducted in approximately 40 centers across the United States.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Observational Group
Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.
Drug: rhIGF-1 (mecasermin, Tercica, Inc.)
Injection of rhIGF-1 80 μg/kg BID
Drug: rhIGF-1 (mecasermin, Tercica, Inc.)
Injection of rhIGF-1 120 μg/kg BID
Drug: rhIGF-1 (mecasermin, Tercica, Inc.)
Twice Daily Injection
Height Velocity During the First Year - Intent to Treat (ITT)Population
Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement.
Time frame: Measured at baseline and at one year
Change From Baseline in Height Standard Deviation (SD) Score at One Year - ITT Population
Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement. Please note that Standard Deviation (SD) Score is a term used in growth studies. The SD Score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child.
Time frame: Measured at baseline and at one year
Changes in Bone Age From Baseline to One Year
Plain X-rays of the left hand and wrist exposed for bone age appraisal. The films are sent to a central facility for standardized evaluation.
Time frame: Measured at baseline and at one year
Percent Changes From Baseline in Serum Concentrations of IGF-1 at One Year
Blood sample was collected while subject is in a fasting state for measuring the level of IGF-1 in the growth factor panel.
Time frame: Measured at baseline and at one year
Percent Changes From Baseline in Serum Concentrations of IGF-2 at One Year
Blood sample was collected for measuring the level of IGF-2 in the growth factor panel.
Time frame: Measured at baseline and at one year
Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) at One Year
Blood sample was collected for measuring the level of insulin-like growth factor binding protein-2 (IGFBP-2) in the growth factor panel.
Time frame: Measured at baseline and at one year
Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) at One Year
Blood sample was collected while subject is in a fasting state for measuring the level of IGFBP-3 in the growth factor panel.
Time frame: Measured at baseline and at one year
IGF Generation Test: Change of Serum IGF-1 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)
Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.
Time frame: Study Day 1 and Day 7
IGF Generation Test: Change of Serum IGFBP-3 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)
Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.
Time frame: Study Day 1 and Day 7
Study Initiation Date: 14 March 2004. Study completion Date: 02 July 2008. 44 investigators screened subjects; 14 did not enroll any subjects. 137 subjects were enrolled. Consent for one randomized subject was withdrawn prior to any study measurements. This subject was excluded from all analyses.
| Milestone | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Started | 25 | 16 | 44 | 51 |
| Completed | 23 | 16 | 40 | 45 |
| Not completed | 2 | 0 | 4 | 6 |
| Withdrew: Adverse event | 0 | 0 | 2 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 | 1 |
Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement.
| cm/yr | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Height Velocity During the First Year - Intent to Treat (ITT)Population | 5.2 ± 1.0 | — | 6.9 ± 1.0 | 7.7 ± 1.5 |
Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement. Please note that Standard Deviation (SD) Score is a term used in growth studies. The SD Score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child.
| SD/year | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Change From Baseline in Height Standard Deviation (SD) Score at One Year - ITT Population | 0.02 ± 0.24 | — | 0.38 ± 0.17 | 0.48 ± 0.32 |
Plain X-rays of the left hand and wrist exposed for bone age appraisal. The films are sent to a central facility for standardized evaluation.
| Year | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Changes in Bone Age From Baseline to One Year | 0.8 ± 0.3 | — | 1.1 ± 0.4 | 1.2 ± 0.5 |
Blood sample was collected while subject is in a fasting state for measuring the level of IGF-1 in the growth factor panel.
| Percent change | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Percent Changes From Baseline in Serum Concentrations of IGF-1 at One Year | 64 ± 120 | — | 227 ± 220 | 266 ± 215 |
Blood sample was collected for measuring the level of IGF-2 in the growth factor panel.
| Percent change | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Percent Changes From Baseline in Serum Concentrations of IGF-2 at One Year | 14 ± 28 | — | -38 ± 37 | -37 ± 32 |
Blood sample was collected for measuring the level of insulin-like growth factor binding protein-2 (IGFBP-2) in the growth factor panel.
| Percent change | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) at One Year | -16 ± 26 | — | 58 ± 84 | 61 ± 79 |
Blood sample was collected while subject is in a fasting state for measuring the level of IGFBP-3 in the growth factor panel.
| Percent change | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) at One Year | 13 ± 33 | — | -19 ± 22 | -19 ± 28 |
Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.
| ng/mL | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| IGF Generation Test: Change of Serum IGF-1 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH) | 40 ± 49 | — | 53 ± 49 | 48 ± 43 |
Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.
| mg/dL | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| IGF Generation Test: Change of Serum IGFBP-3 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH) | 744 ± 459 | — | 800 ± 1095 | 681 ± 568 |
Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement.
| cm/year | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Height Velocity During the First Year for Subjects - Completers | 5.2 ± 1.0 | — | 7.0 ± 1.0 | 7.9 ± 1.4 |
Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement. Please note that Standard Deviation (SD) Score is a term used in growth studies. The SD Score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child.
| SD/year | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| Change From Baseline in Height Standard Deviation (SD) Score at One Year - Completers | 0.02 ± 0.24 | — | 0.39 ± 0.17 | 0.53 ± 0.30 |
Collected over Adverse events were collected until 30 days after last subject visit or until resolution. Adverse event collection for an individual subject was 1 year 1 month. Across study adverse event reporting continued for a total of 4 years 5 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Untreated | — | 1/25 (4%) | 18/25 (72%) |
| 40 μg/kg BID (Twice Daily Dosing) | — | 1/16 (6.3%) | 16/16 (100%) |
| 80 μg/kg BID (Twice Daily Dosing) | — | 2/44 (4.5%) | 37/44 (84.1%) |
| 120 μg/kg BID (Twice Daily Dosing) | — | 5/51 (9.8%) | 43/51 (84.3%) |
| Event | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| GastroenteritisGastrointestinal disorders | 0/25 | 1/16 | 0/44 | 0/51 |
| VomitingGastrointestinal disorders | 0/25 | 1/16 | 0/44 | 0/51 |
| CellulitisInfections and infestations | 1/25 | 0/16 | 0/44 | 0/51 |
| Gastroenteritis escherichia coliGastrointestinal disorders | 0/25 | 0/16 | 1/44 | 0/51 |
| Intracranial pressure increasedNervous system disorders | 0/25 | 0/16 | 1/44 | 0/51 |
| Cor TriatriatumCongenital, familial and genetic disorders | 0/25 | 0/16 | 0/44 | 1/51 |
| Hypoglycemic seizureEndocrine disorders | 0/25 | 0/16 | 0/44 | 1/51 |
| Gastroenteritis viralInfections and infestations | 0/25 | 0/16 | 0/44 | 1/51 |
| PneumoniaInfections and infestations | 0/25 | 0/16 | 0/44 | 1/51 |
| DehydrationMetabolism and nutrition disorders | 0/25 | 0/16 | 0/44 | 1/51 |
| Event | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 4/25 | 8/16 | 13/44 | 21/51 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/25 | 4/16 | 10/44 | 7/51 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/25 | 4/16 | 5/44 | 5/51 |
| NauseaGastrointestinal disorders | 0/25 | 4/16 | 6/44 | 2/51 |
| Upper respiratory tract infectionInfections and infestations | 6/25 | 3/16 | 10/44 | 12/51 |
| Gastroenteritis viralInfections and infestations | 0/25 | 3/16 | 8/44 | 3/51 |
| Injection site bruisingGeneral disorders | 0/25 | 3/16 | 6/44 | 4/51 |
| Otitis mediaInfections and infestations | 3/25 | 3/16 | 2/44 | 4/51 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 0/25 | 3/16 | 4/44 | 4/51 |
| GastroenteritisGastrointestinal disorders | 0/25 | 3/16 | 4/44 | 3/51 |
| Age, Continuous(years) | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) | Total |
|---|---|---|---|---|---|
| Mean | 7.0 ± 2.4 | 7.6 ± 2.4 | 7.7 ± 2.4 | 7.6 ± 2.7 | 7.5 ± 2.5 |
| Sex: Female, Male(Participants) | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) | Total |
|---|---|---|---|---|---|
| Female | 10 | 4 | 14 | 8 | 36 |
| Male | 15 | 12 | 30 | 43 | 100 |
| Race/Ethnicity, Customized(participants) | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) | Total |
|---|---|---|---|---|---|
| Asian | 1 | 0 | 1 | 2 | 4 |
| Black | 0 | 0 | 0 | 2 | 2 |
| Hispanic | 2 | 0 | 4 | 4 | 10 |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| White | 22 | 16 | 38 | 41 | 117 |
| Other | 0 | 0 | 1 | 1 | 2 |
| Stratum(participants) | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) | Total |
|---|---|---|---|---|---|
| Height Standard Deviation Score < -2.6 | 13 | 8 | 25 | 30 | 76 |
| Height Standard Deviation Score >= -2.6 | 12 | 8 | 19 | 21 | 60 |
| Height Standard Deviation (SD) Score(SD) | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) | Total |
|---|---|---|---|---|---|
| Mean | -2.8 ± 0.7 | -2.6 ± 0.6 | -2.7 ± 0.5 | -2.9 ± 0.8 | -2.8 ± 0.7 |
| IGF-1 Standard Deviation (SD) Score(SD) | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) | Total |
|---|---|---|---|---|---|
| Mean | -2.6 ± 0.7 | -2.8 ± 0.8 | -2.6 ± 0.7 | -3.0 ± 0.8 | -2.8 ± 0.8 |
| Maximum Stimulated Growth Hormone(ng/mL) | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) | Total |
|---|---|---|---|---|---|
| Mean | 17.0 ± 6.5 | 16.9 ± 6.2 | 17.8 ± 9.0 | 20.7 ± 16.8 | 18.6 ± 12.1 |
| Weight(Kg) | Untreated | 40 μg/kg BID (Twice Daily Dosing) | 80 μg/kg BID (Twice Daily Dosing) | 120 μg/kg BID (Twice Daily Dosing) | Total |
|---|---|---|---|---|---|
| Mean | 17.8 ± 4.6 | 18.5 ± 4.7 | 19.4 ± 5.4 | 18.5 ± 5.7 | 18.6 ± 5.3 |
The record gives a start of Mar 2004, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mecasermin